Protection of mice against SV40 tumours by Pam3Cys, MTP-PE and Pam3Cys conjugated with the SV40 T antigen-derived peptide, K(698)-T(708)

Vaccine

Volumn 16, Issue 2-3, 1998, Pages 161-169

  Obert, Matthias ^a   Pleuger, Hendrik ^a   Hanagarth, Hans Günter ^a   Schulte Mönting, Jürgen ^b   Wiesmüller, Karl Heinz ^c   Braun, Dietmar G ^a   Brandner, Gerhard ^a   Hess, Ralf D ^a,d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d NONE   (Germany)

Author keywords

Pam3Cys Muramyl tripeptide phosphatidylethanolamine; S 2,3 bis(palmitoyloxy) (2 RS) propyl N palmitoyl R cysteine; Simian virus 40 transformed cells; SV40; Synthetic adjuvants; Tumour immunity; Tumour resistance; Tumour vaccine; VLM

Indexed keywords

ADJUVANT; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNITY; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; PROTECTION; SIMIAN VIRUS 40; TUMOR; TUMOR RESISTANCE;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, VIRAL, TUMOR; BIOLOGICAL RESPONSE MODIFIERS; CYSTEINE; FEMALE; IMMUNIZATION; LIPOPROTEINS; MICE; MICE, INBRED BALB C; OLIGOPEPTIDES; PAPILLOMAVIRUS INFECTIONS; PHOSPHATIDYLETHANOLAMINES; SIMIAN VIRUS 40; TUMOR VIRUS INFECTIONS;

EID: 0031986203     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00181-3     Document Type: Article

References (57)

1. 1 Tooze, J. Molecular Biology of Tumor Viruses: DNA Tumor Viruses. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1980.
2. 2 Schreiber, H. Fundamental Immunology. Raven Press, New York, 1989.
3. 3 Tevethia, S.S., Flyer, D.C. and Tjian, R. Biology of simian virus 40 (SV40) transplantation antigen (TrAg). VI. Mechanism of induction of SV40 transplantation immunity in mice by purified SV40 T antigen (D2 protein). Virology 1980, 107, 13-23.
4. 4 Chang, C., Chang, R., Mora, P.T. and Hu, C.P. Relationship between T antigen and tumor-specific transplantation antigen in simian virus 40-transformed cells. J. Virol. 1979, 29, 69-75.
5. 5 Campbell, A.E., Foley, F.L. and Tevethia, S.S. Demonstration of multiple antigenic sites of the SV40 transplantation rejection antigen by using cytotoxic T lymphocyte clones. J. Immunol. 1983, 130, 490-492.
6. 6 Gooding, L.R. and O'Connell, K.A. Recognition by cytotoxic T lymphocytes of cells expressing fragments of the SV40 tumor antigen. J. Immunol. 1983, 131, 2580-2586.
7. b-restricted cytotoxic T-lymphocyte clones and a synthetic peptide. Virology 1989, 171, 205-213.
8. 8 Deckhut, A.M., Tevethia, M.J., Haggerty, S., Frisque, R.J. and Tevethia, S.S. Localization of common cytotoxic T lymphocyte recognition epitopes on simian papovavirus SV40 and human papovavirus JC virus T antigens. Virology 1991, 183, 122-132.
9. 9 Carlsson, J., Drevin, H. and Axen, R. Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent. Biochem. J. 1978, 173, 723-735.
10. 10 Hess, R., Rau, P, and Schwab, M. et. al. Covalent immunochemical membrane labelling of viable cells with K698-T708, a simian virus 40 tumour antigen-derived peptide. Peptide Res. 1994, 7, 146-152.
11. 11 Hanagarth, H., Obert, M., Hess, R., Haessler, C., Braun, D.G. and Brandner, G. The cell-binding carboxyterminal undecapeptide of SV40 tumour antigen provides protective cell-dependent immunity. Vaccine 1994, 12, 1197-1202.
12. 12 Hess, R.D., Kuther, M., Haessler, C., Paetzold, S., Braun, D.G. and Brandner, G. Quantitative cytofluorimetric determination of cell-membrane-associaed large tumour antigen on SV40-transformed cells. Cytometry 1995, 20, 81-85.
13. 13 Tevethia, S.S. and Zarling, J.M. Participation of macrophages in tumor immunity. Natl. Cancer Inst. Monograph 1972, 35, 279-282.
14. 14 Fresa, K.L., Karjalainen, H.E. and Tevethia, S.S. Sensitivity of simian virus 40-transformed C57BL/6 mouse embryo fibroblasts to lysis by murine natural killer cells. J. Immunol. 1987, 138, 1215-1220.
15. 15 Talmadge, J.E., Schneider, M., Collins, M., Herberman, R.B. and Wiltrout, R.H. Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE. J. Immunol. 1985, 135, 1477-1483.
16. 16 Deres, K.H., Schild, K.H., Wiesmüller, K.-H., Jung, G. and Rammensee, H.G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 1989, 342, 561-564.
17. 17 Hoffmann, P., Jimenez, D.M. and Loleit, M. Preparation of human and murine monoclonal antibodies: antigens combined with or conjugated to lipopeptides constitute potent immunogens for in vitro and in vivo immunizations. Hum. Antibodies. Hybridomas. 1990, 1, 137-144.
18. 18 Wiesmüller, K.H., Jung, G. and Hess, G. Novel low-molecular weight synthetic vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator. Vaccine 1989, 7, 29-33.
19. 19 Reitermann, A., Metzger, J., Wiesmüller, K.-H., Jung, G. and Bessler, W.G. Lipopeptide derivatives of bacterial lipoprotein constitute potent immune adjuvants combined with or covalently coupled to antigen or hapten. Biol. Chem. Hoppe Seyler 1989, 370, 343-352.
20. 20 Schild, H., Deres, K., Wiesmüller, K.-H., Jung, G. and Rammensee, H.G. Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells. Eur. J. Immunol. 1991, 21, 2649-2654.
21. 21 Borges, E., Wiesmüller, K.H., Jung, G. and Walden, P. Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocytes. Compariston of the costimulating support provided by helper T cells and lipoamino acid. J. Immunol. Meth. 1994, 173, 253-263.
22. 22 Hoffmann, P., Heinle, S. and Schade, U.F. et al. Stimulation of human and murine adherent cells by bacterial lipoprotein and synthetic lipopeptide analogues. Immunobiology 1988, 177, 158-170.
23. 23 Hoffmann, P., Wiesmüller, K.-H., Metzger, J., Jung, G. and Bessler, W.G. Induction of tumor cytotoxicity in murine bone marrow-derived macrophages by two synthetic lipopeptide analogues. Biol. Chem. Hoppe Seyler 1989, 370, 575-582.
24. 3Cys-Ser-(Lys)4. Involvement of guanine-nucleotide-binding proteins and synergism with chemotactic peptides. Biochem. J. 1990, 267, 795-802.
25. 25 Seifert, R., Serke, S. and Huhn, D. et al. Incomplete functional differentiation of HL-60 leukemic cells by synthetic lipopeptides. Partial inhibition by pertussis toxin of enhanced superoxide formation. Eur. J. Biochem. 1992, 203, 143-151.
26. 2+. Biochem. J. 1990, 270, 351-356.
27. 27 Hauschildt, S., Hoffmann, P. and Beuscher, H.U. et al. Activation of bone marrow-derived mouse macrophages by bacterial lipopeptide: cytokine production, phagocytosis and la expression. Eur. J. Immunol. 1990, 20, 63-68.
28. 28 Hauschildt, S., Bassenge, E., Bessler, W., Busse, R. and Mulsch, A.L. L-arginine-dependent nitric oxide formation and nitrite release in bone marrow-derived macrophages stimulated with bacterial lipopeptide and lipopolysaccharide. Immunology 1990, 70, 332-337.
29. 29 Schlecht, S., Wiesmüller, K.-H., Jung, G. and Bessler, W.G. Enhancement of protection against Salmonella infection in mice mediated by a synthetic lipopeptide analogue of bacterial lipoprotein in S. typhimurium vaccines. Int. J. Med. Microbiol. 1989, 271, 493-500.
30. 30 Zarling, J.M. and Tevethia, S.S. Transplantation immunity to simian virus 40-transformed cells in tumor-bearing mice. I. Development of cellular immunity to simian virus 40 tumor-specific transplantation antigens during tumorigenesis by transformed cells. J. Natl. Cancer Inst. 1973, 50, 137-147.
31. 31 Metzger, J.W., Beck, W. and Jung, G. Ion-spray mass spectrometry of lipopeptide vaccines. Angw. Chem. Int. Ed. Engl. 1992, 31, 226-228.
32. 32 Van Hoogevest, P. and Fankhauser, P. Liposomes in the therapy of infectious disease and cancer. In: 1985, UCLA Symposia on Molecular and Cellular Biology (Eds Berestein, L. and Fidler, A.R.). Liss, New York, pp. 453-466.
33. 33 Hahn, H. Effects of dextrane sulfate 500 on cell-mediated resistance to infection with listeria monocytogenes in mice. Infect Immunol. 1974, 10, 1105-1109.
34. 34 Marcus, R., Peritz, E. and Gabriel, K.R. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1983, 63, 655-660.
35. 35 Scheffe, H. A method for judging all contrasts in the analysis of variance. Biometrika 1953, 40, 87-104.
36. 36 Bessler, W.G. and Jung, G. Synthetic lipopeptides as novel adjuvants. Res. Immunol. 1992, 143, 548-533.
37. 37 Bessler, W.G., Cox, M., Lex, A., Suhr, B., Wiesmüller, K.H. and Jung, G. Synthetic analogues of bacterial lipoprotein are potent polyclonal activators for murine B lymphocytes. J. Immunol. 1985, 135, 1900-1905.
38. 38 Utsugi, T., Dinney, C.P., Killion, J.J., Brown, D. and Fidler, I-J. In situ activation of mouse lung macrophages by coadministration of liposomes containing the lipopeptide CGP31362 and interleukin 2 involves interaction with T lymphocytes and natural killer cells. Lymphokine Cytokine Res. 1991, 10, 487-493.
39. 39 Utsugi, T., Dinney, C.P., Killion, J.J. and Fidler, I.J. In situ activation of mouse macrophages and therapy of spontaneous renal cancer metastasis by liposomes containing the lipopeptide CGP31362. Cancer Immunol. Immunother. 1991, 33, 375-381.
40. 40 Asano, T. and Kleinerman, E.S. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J. Immunother. 1993, 14, 286-292.
41. 41 Braun, D.G., Hoogevest, P. van and Schumann, G. Muramytripeptidephosphatidylethanolamine (MTP-PE) - a muramyltripeptide derivative with lipophilic properties. In: Adjuvants: Theory and Practical Applications (Ed. Stewart-Tull, D.E.S.). Butterworth, Heinemann, Oxford, 1992
42. 42 Fidler, I.J., Fogler, W.E., Tarcsay, L., Schumann, G. Braun, D.G. and Schroit, A.J. Systemic activation of macrophages and treatment of cancer metastases by liposomes containing hydrophilic or lipophilic muramyl dipeptide. In: Advances in Immunopharmacology 2 (Eds Hadden, J.W., Chedid, L., Dukor, P., Spreafico, F. and Willoughbhy, D.). Pergamon Press, Oxford, 1983.
43. 43 Brownbill, A.F., Braun, D.G., Dukor, P. and Schumann, G. Induction of tumouricidal leucocytes by the intranasal application of MTP-PE, a lipophilic muramyl peptide. Cancer Immunol. Immunother. 1985, 20, 11-17.
44. 44 MacEwen, E.G., Kurzman, I.D., Rosenthal, and R., et al. Therapy of osteosarcoma in dogs with intraveneous injection of liposome-encapsulated muramyl tripeptide. J. Natl. Cancer Inst. 1989, 81, 935-938.
45. 45 Malik, S.T.A., Martin, D. and Balkwill Hart, F. Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF. Br. J. Cancer 1991, 643, 399-403.
46. 46 Melissen, P.M.B., Vianen van, W. and Bakker-Woudenberg, I.A.J.M. Treatment of Klebsiella pneumoniae septicemia in normal and leukopenic mice by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine. Antimicrobial Agents Chemother. 1994, 38, 147-150.
47. 47 Lazdins, U.K., Woods-Cook, K., Walker, M. and Alteri, E. The lipophilic muramyl peptide MTP-PE is a potent inhibitor of HIV replication in macrophages. AIDS Res. Human Retrov. 1990, 6, 1157-1161.
48. 48 Lowell, G.H., Ballou, W.R., Smith, F.L., Wirtz, R.A., Zollinger, W.D. and Hockmeyer, W.T. Proteosome-lipopeptide vaccines: enhancement of imunogenicity for malaria CS peptide. Science 1988, 240, 800-802.
49. 49 Kozono, H., White, J., Clements, J., Marrack, P. and Kappler, J. Production of soluble MHC class II proteins with covalently bound single peptides. Nature 1994, 369, 151-154.
50. 50 Zitvogel, L., Mayordomo, J.I. and Tjandrawan, T. et al. Therapy of murine tumours with tumour peptide pulsed dendritic cells: dependence on T cells, B7 costimulation, and Th1-associated cytokines. J. Exp. Med. 1996, 183, 87-97.
51. 51 Celluzi, C.M., Mayordomo, J.I., Storkus, W.J., Lotze, M.T. and Falo F.D. Peptide-pulsed dendritic cells induce antigen-specific. CTL-mediated protective tumour immunity. J. Exp. Med. 1996, 183, 283-287.
52. 52 Paglia, P.C., Chiodoni, M., Rodolfo, M. and Colombo, M.P. Murine dendritic cells loaded in vitro with soluble protein prime CTL against tumour antigen in vivo. J. Exp. Med. 1996, 183, 317-322.
53. 53 Cohen, P.J., Cohen, P.A., Rosenberg, S.A., Katz, S.I. and Mule, J.J. Murine epidermal Langerhans cells and spleenic dendritic cells present tumour-associated antigens to prime T cells. Eur. J. Immunol. 1994, 24, 315-319.
54. 54 Flammand, V., Sornasse, K. and Thielemans. K. et al. Murine dendritic cells pulsed in vitro with tumour-antigen induce tumour resistance in vivo. Eur. J. Immunol. 1994, 24, 605-610.
55. 55 Young, J.W. and Inaba, K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumour immunity. J. Exp. Med. 1996, 183, 7-11.
56. 56 Mandelboim, O., Vadai, E. and Fridkin, M. et al. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptide. Nature Med. 1995, 1, 1179-1183.
57. 57 Strominger, J.L. Peptide vaccination against cancer? Nature Med. 1995, 1, 1140.